Issue of Equity

RNS Number : 9812Y
Physiomics PLC
19 January 2022
 

19 January 2022

Physiomics plc

("Physiomics" or "the Company")

 

Issue of Equity

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, announces that following the receipt of a notice of exercise of employee options, 90,000 ordinary shares of 0.4p each in the Company ("Ordinary Shares") (the "Options Shares") will be issued to an employee at an exercise price of 3.16p per option.

 

Application will be made for the Option Shares, which will rank pari passu with the Company's existing Ordinary Shares, to be admitted to trading on AIM, and dealings in the Option Shares are expected to commence on 25 January 2022 ("Admission").  Following Admission, the total number of Ordinary Shares in issue will increase to 97,424,778.

 

For the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules (the "DTRs"), the issued ordinary share capital of the Company following Admission will consist of 97,424,778 Ordinary Shares with voting rights attached (one vote per Ordinary Share).  There are no Ordinary Shares held in treasury.  This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the DTRs.  The Company's share capital additionally comprises 2,481,657,918 deferred shares of 0.036p each which are not quoted and to which no voting rights attach.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEAAFNFFFAEFA

Companies

Physiomics (PYC)
UK 100

Latest directors dealings